{"filings":[{"id":96704,"accession_number":"0001193125-26-173690","cik":1913577,"company_name":"Semnur Pharmaceuticals, Inc.","ticker":"SMNR","form_type":"8-K","filed_at":"2026-04-23T23:59:59+00:00","items":["1.02"],"status":"ready","headline":"Semnur terminates two material financing agreements totaling $120M in potential proceeds","event_type":"other_material","confidence":"high","bullets":["Terminated PIPE SPA with JW Capital Securities Ltd for 1.25M shares at $16/share ($20M).","Terminated Semnur/Biconomy SPA for 6.25M shares at $16/share payable in Bitcoin ($100M).","No shares were ever issued under either agreement; both terminations effective April 20, 2026.","Company delivered termination notices under Section 8 of each SPA."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":110836,"accession_number":"0001193125-26-110816","cik":1913577,"company_name":"Semnur Pharmaceuticals, Inc.","ticker":"SMNR","form_type":"8-K","filed_at":"2026-03-17T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"CEO Jaisim Shah retires; Henry Ji appointed CEO and President; Stephen Ma named COO","event_type":"leadership","confidence":"high","bullets":["Jaisim Shah resigned as CEO, President, and director effective March 13, 2026; retirement not due to any disagreement.","Henry Ji (age 61), formerly Executive Chairperson, appointed CEO and President; also CEO of Scilex (SCLX) and Vivasor.","Stephen Ma, previously CFO and Secretary, appointed COO effective March 17, 2026; also COO of Scilex.","Shah receives six months base salary ($1,250,000/yr) and 90-day extension to exercise vested stock options per separation agreement.","Board size reduced from six to five directors following Shah's resignation."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":127458,"accession_number":"0001193125-25-306757","cik":1913577,"company_name":"Semnur Pharmaceuticals, Inc.","ticker":"SMNR","form_type":"8-K","filed_at":"2025-12-03T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Semnur Pharmaceuticals files updated securities description reflecting charter and bylaws amendments","event_type":"other_material","confidence":"medium","bullets":["Updates description of common stock and warrants per amendments to certificate of incorporation and bylaws since 2024 year-end.","Securities continue to trade on OTCQB under symbols SMNR and SMNRW; no change in trading status.","No material financial or operational events disclosed; filing is administrative in nature."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":144255,"accession_number":"0001193125-25-220455","cik":1913577,"company_name":"Semnur Pharmaceuticals, Inc.","ticker":"SMNR","form_type":"8-K","filed_at":"2025-09-26T23:59:59+00:00","items":["1.01","2.01","9.01","5.02","3.02","4.01","2.03","3.03","8.01","5.01","5.03","5.05","5.06","7.01"],"status":"ready","headline":"Semnur completes de-SPAC merger with Denali; trades under SMNR on OTCQB","event_type":"m_and_a","confidence":"high","bullets":["Business combination closed Sept 22, 2025; Legacy Semnur becomes wholly owned subsidiary of New Semnur.","Exchange ratio of 1.25; SHC contributed $54.2M intercompany debt for 5.4M shares of Legacy Semnur preferred.","Entered Securities Purchase Agreement with Biconomy PTE.LTD for 6.25M shares at $16/share payable in Bitcoin.","Settled underwriter deferred discount and sponsor/futuretech debts with cash, shares, and promissory notes.","Trading symbols changed to SMNR (common) and SMNRW (warrants) on OTCQB."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.85,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":144254,"accession_number":"0001213900-25-084180","cik":1913577,"company_name":"Semnur Pharmaceuticals, Inc.","ticker":"SMNR","form_type":"8-K","filed_at":"2025-09-04T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Shareholders approve merger with Semnur Pharmaceuticals at September 3 meeting","event_type":"other_material","confidence":"high","bullets":["All 9 proposals, including business combination with Semnur, approved by 94.08% quorum.","Domestication from Cayman Islands to Delaware and amended charter/bylaws approved.","New board of directors elected: Jaisim Shah, Henry Ji, Jay Chun, Dorman Followwill, Yue Alexander Wu.","Issuance of >20% of Denali shares and conversion of Semnur options into New Semnur options approved."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":144253,"accession_number":"0001213900-25-079504","cik":1913577,"company_name":"Semnur Pharmaceuticals, Inc.","ticker":"SMNR","form_type":"8-K","filed_at":"2025-08-22T23:59:59+00:00","items":["1.01","3.02","9.01"],"status":"ready","headline":"Denali Capital enters $20M PIPE at $16/share and 12M share escrow for Semnur merger","event_type":"m_and_a","confidence":"high","bullets":["PIPE purchase of 1.25M shares at $16.00 each for $20M total from a single purchaser.","Shares sold exempt under Section 4(a)(2) and Rule 506(b); restricted securities.","Semnur to deposit 12M shares of New Semnur common stock into escrow within 20 business days post-closing.","Closing conditioned on business combination; termination date for PIPE is Dec 31, 2025.","Merger agreement (amended) with Denali Merger Sub Inc. and Semnur; S-4 effective Aug 12, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":144252,"accession_number":"0001213900-25-073907","cik":1913577,"company_name":"Semnur Pharmaceuticals, Inc.","ticker":"SMNR","form_type":"8-K","filed_at":"2025-08-11T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Denali Capital extends SPAC deadline to Sep 11, 2025 with $874.78 trust deposit","event_type":"other_material","confidence":"high","bullets":["Deposited $874.78 into trust account to extend business combination deadline by one month.","Extension moves deadline from August 11, 2025 to September 11, 2025.","No business combination announced; extension provides additional time to complete a deal."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":144251,"accession_number":"0001213900-25-068263","cik":1913577,"company_name":"Semnur Pharmaceuticals, Inc.","ticker":"SMNR","form_type":"8-K","filed_at":"2025-07-28T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Denali Capital Acquisition Corp. enters Amendment No. 2 to Merger Agreement with Semnur Pharmaceuticals","event_type":"m_and_a","confidence":"high","bullets":["Amendment No. 2 signed on July 22, 2025 modifies Exchange Ratio and Merger Consideration definitions.","Allows issuance of additional Semnur common shares pre-closing for private placement financing or advisor services.","Maintains the 1.25-to-1 exchange ratio between Denali and Semnur shares.","Parties include Denali Capital Acquisition Corp., Denali Merger Sub Inc., and Semnur Pharmaceuticals (Scilex subsidiary)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":144250,"accession_number":"0001213900-25-063294","cik":1913577,"company_name":"Semnur Pharmaceuticals, Inc.","ticker":"SMNR","form_type":"8-K","filed_at":"2025-07-11T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Denali Capital extends combination deadline to Aug 11, 2025 with $874.78 deposit","event_type":"other_material","confidence":"high","bullets":["Deposited $874.78 into trust account to extend deadline by one month to August 11, 2025.","Previous deadline was July 11, 2025.","Extension provides additional time to consummate initial business combination."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":162616,"accession_number":"0001213900-25-053576","cik":1913577,"company_name":"Semnur Pharmaceuticals, Inc.","ticker":"SMNR","form_type":"8-K","filed_at":"2025-06-12T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Denali Capital Acquisition Corp. extends business combination deadline to July 11, 2025","event_type":"other_material","confidence":"high","bullets":["Deposited $874.78 into trust account to extend deadline from June 11 to July 11, 2025.","Extension funded via convertible promissory note from Scilex Holding (SCLX) with principal up to $180,000.","Note bears no interest, convertible at $10.00/share upon business combination; remaining $56,920.74 available for future extensions.","Note repayable on earlier of business combination or liquidation of the company."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":162615,"accession_number":"0001213900-25-041653","cik":1913577,"company_name":"Semnur Pharmaceuticals, Inc.","ticker":"SMNR","form_type":"8-K","filed_at":"2025-05-12T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Denali Capital extends business combination deadline to June 11, 2025 with $874.78 trust deposit funded by Scilex note","event_type":"other_material","confidence":"high","bullets":["Deposited $874.78 into trust account to extend deadline from May 11 to June 11, 2025.","Deposit funded by convertible promissory note from Scilex (SCLX) with principal up to $180,000, no interest.","Note convertible at Scilex's discretion into Class A shares at $10.00 per share upon business combination close.","Remaining $57,795.52 available under note expected to fund future one-month extensions if needed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":162614,"accession_number":"0001213900-25-034254","cik":1913577,"company_name":"Semnur Pharmaceuticals, Inc.","ticker":"SMNR","form_type":"8-K","filed_at":"2025-04-22T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Denali Capital amends merger pact with Semnur; extends deadline to Sept 2025, addresses Nasdaq delisting","event_type":"m_and_a","confidence":"high","bullets":["Amendment allows Denali to extend business combination deadline to Dec 11, 2025, or later if mutually agreed.","Outside Date for closing merger extended to Sept 30, 2025; if extension effective, Outside Date becomes Extension Date.","Modifies covenants to address Denali's Nasdaq delisting and subsequent OTC Markets quotation of its securities.","Denali will use reasonable best efforts to list its units, shares, and warrants on OTC Markets after Nasdaq delisting.","Other changes include updating blank-check company status and proxy statement requirements for shareholder vote."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":162613,"accession_number":"0001213900-25-032299","cik":1913577,"company_name":"Semnur Pharmaceuticals, Inc.","ticker":"SMNR","form_type":"8-K","filed_at":"2025-04-16T23:59:59+00:00","items":["5.07","8.01","9.01"],"status":"ready","headline":"Denali Capital shareholders approve extension to Dec 2025; ~708K shares redeemed for ~$8.6M","event_type":"other_material","confidence":"high","bullets":["Shareholders voted to extend business combination deadline to December 11, 2025, via up to 8 monthly extensions.","Holders of ~708,098 Class A shares redeemed for ~$8.6M (~$12.17/share); only 43,739 Class A shares remain outstanding.","Company deposited $874.78 into trust for first extension to May 11, 2025, funded by Scilex convertible note (up to $180K).","Scilex note bears no interest, convertible at $10/share; remaining $58,670.30 available for future extensions."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":162612,"accession_number":"0001213900-25-030048","cik":1913577,"company_name":"Semnur Pharmaceuticals, Inc.","ticker":"SMNR","form_type":"8-K","filed_at":"2025-04-09T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Denali Capital receives Nasdaq delisting determination; must appeal by April 9 or face suspension","event_type":"other_material","confidence":"high","bullets":["On April 2, 2025, Nasdaq staff determined Denali failed to meet MVLS, total assets, and public float rules.","Company must appeal by April 9, 2025 to avoid delisting; if no appeal, trading suspended April 11, 2025.","Company expects to trade on OTC market after delisting; plans to remain a reporting company.","Delisting not expected to immediately impact planned business combination with Semnur Pharmaceuticals."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":180612,"accession_number":"0001213900-25-022858","cik":1913577,"company_name":"Semnur Pharmaceuticals, Inc.","ticker":"SMNR","form_type":"8-K","filed_at":"2025-03-12T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Denali Capital extends business combination deadline to April 11 via $15K trust deposit","event_type":"other_material","confidence":"high","bullets":["Deposited $15,063.74 into trust to extend deadline from March 11 to April 11, 2025.","Funding via convertible promissory note from Scilex (SCLX) with principal up to $180,000.","Note bears no interest, convertible into Class A shares at $10.00 per share upon closing.","Remaining $59,545.08 under note available for future one-month extensions.","Company is a blank check SPAC seeking a merger or acquisition."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}